AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health to address critical unmet challenges in women’s health, champion transformative innovations, and tackle health conditions that uniquely or disproportio ...

AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has received approval from the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) for OvaWatch®, the Company’s non-invasive blood test for the assessment of ovarian cancer risk for women with an adnexal mass determined by initial ...

Annex Insurance (AWH, Financial) stock recently experienced a sharp decline, dropping 7.47% to $0.761 per share. The trading volume stood at 16,266 shares, with a turnover rate of 0.10% and a price fluctuation of 2.62%.Recent financial reports show Annex Insurance faced significant challenges, recording a revenue of $2.42 million but a net loss of $3.53 million. Earnings per share were reported at -$0.28, with a gross profit of $1.42 million and a negative price-to-earnings ratio of -0.58. Currently, no ins ...

Aspira Womens Health (AWH, Financial) experienced a significant stock price drop of 7.80%, reaching $0.775 per share. The trading volume stood at 14,064 shares with a turnover rate of 0.09% and a volatility of 7.47%.Recent financial results for Aspira Womens Health revealed an operating revenue of $2.42 million and a net loss of $3.53 million, resulting in an earnings per share (EPS) of -$0.28. The gross profit was recorded at $1.42 million, with a price-to-earnings ratio of -0.57. Currently, no institution ...

Aspira Women’s Health Inc. (AWH) has taken a significant step forward in advancing the clinical treatment of adnexal masses by entering into a definitive agreement with Dorsata, a healthcare software company. This strategic partnership aims to create a custom protocol workflow tool, or Module, designed to enhance clinical practices for women's health in the management of adnexal masses.This partnership is expected to work on complications surrounding adnexal masses diagnosis and treatment, a condition that ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------|-------------------------------------------| | | | | For the transition | ______ | | Commission | 001-34810 | | As ...

Aspira Women's Health Inc. (NASDAQ:AWH) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Nicole Sandford - CEO and Director Sandy Milligan - President Conference Call Participants Ross Osborn - Cantor Fitzgerald Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen. And welcome to Aspira Women's Health, Incorporated Second Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. As a reminder, this is call being record ...

Aspira (AWH) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this diagnostic and bio-analytical company would post a loss of $0.36 per share when it actually produced a loss of $0.39, delivering a surprise of -8.33%.Over the last four quarters, the ...

Aspira Women's Health Reports Second Quarter 2024 Financial Results Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, August 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the developme ...

Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financi ...